The global anti-obesity drugs market is expected to grow at a CAGR of 27.1% in the first half of the forecast period and CAGR of 38.7% in the second half of the forecast period. The market is expected to grow at a CAGR of 32.8% from 2016 to 2027. The market is estimated at $1,058 million in 2016, $3,513 million in 2021, and $24,063 million in 2027.
How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 205-page report you will receive 78 tables and 140 figures – all unavailable elsewhere.
The 205-page report provides clear detailed insight into the global anti-obesity drugs market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand new report today you stay better informed and ready to act.
Report Scope
• Global Anti-Obesity Drugs market forecasts from 2017-2027
• Anti-Obesity Drugs National market forecasts from 2017-2027, covering:
– United States
– Germany
– France
– United Kingdom
– Italy
– Spain
– Japan
– China
– India
– Brazil
– Russia
– RoW
• Anti-Obesity Drugs submarket forecasts from 2017-2027, by Mechanisms of Action:
– Incretin mimetics/GLP-1 agonists
– SNDRIs
– Lipase inhibitors
– Serotonin receptor agonists
– Sympathomimetic-GABA receptor agonists
– Sympathomimetics
– Others
• Anti-Obesity Drugs submarket forecasts from 2017-2027, by Duration of Therapy:
– Short-term Drugs
– Long-term Drugs
• Anti-Obesity Drugs submarket forecasts from 2017-2027, segmented by Innovator vs Generic Drugs
• Anti-Obesity Drugs submarket forecasts from 2017-2027, segmented by Prescription vs OTC Drugs
• Analysis of the key factors driving and restraining the growth of the anti-obesity drugs market from 2017-2027
• Pricing and Reimbursement overview of the anti-obesity drugs market
• Assessment of selected leading companies that hold major market shares in the anti-obesity drugs market.
Visiongain’s study is intended for anyone requiring commercial analyses for the Anti-Obesity Drugs Market and leading companies. You find data, trends and predictions.
Buy our report today Global Anti-Obesity Drugs Market Forecast 2017-2027: Incretin Mimetics/GLP-1 Agonists, SNDRIs, Lipase Inhibitors, Serotonin Receptor Agonists, Sympathomimetic-GABA Receptor Agonists, Sympathomimetics and Others.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
1. Report Overview
1.1 Why You Should Read This Report
1.2 How This Report Delivers
1.3 Key Questions Answered by This Analytical Report
1.4 Who is This Report for?
1.5 Methodology
1.5.1 Primary Research
1.5.2 Secondary Research
1.5.3 Market Evaluation & Forecasting Methodology
1.6 Frequently Asked Questions
1.7 Associated Reports
1.8 About Visiongain
2. Introduction to Obesity
2.1 What is Obesity?
2.1.1 Types of obesity
2.1.1.1 Central Obesity / Android Type
2.1.1.2 Peripheral Obesity/ Gynoid Type
2.2 What are the causes and risk factors of obesity?
2.2.1 Energy Imbalance
2.2.2 Genetic Predisposition
2.2.3 Unhealthy Diet
2.2.4 Health Conditions and Medicines
2.2.5 Emotional Factors
2.2.6 Age
2.2.7 Pregnancy
2.2.8 Lack of Sleep
2.2.9 Smoking
2.3 Obesity Measurement
2.3.1 BMI
2.3.2 Waist circumference
2.3.3 Index of Central Obesity
2.3.4 Bioelectrical Impedance Analysis
2.3.5 New Approaches/Techniques
2.4 Epidemiology of Obesity
2.4.1 Epidemiology by Geography
2.4.2 Epidemiology by Country
2.4.3 Historical Prevalence in Major Markets
2.4.1 Forecast of Obesity Prevalence in Major Markets
2.5 Humanistic and Economic Burden
2.5.1 Mortality
2.5.2 Morbidity
2.5.2.1 Disability-adjusted life year (DALY)
2.5.2.2 Years Lost due to Disability (YLD)
2.5.2.3 Years of Life Lost(YLL)
2.5.2.3.1 Type-2 diabetes
2.5.2.3.2 Dyslipidaemia
2.5.2.3.3 Hypertension
2.5.2.3.4 Stroke & Heart failure
2.5.2.3.5 Non-alcoholic fatty liver disease (NAFLD)
2.5.2.3.6 Osteoarthritis
2.5.2.3.7 Psychological disorders
2.5.3 Economic Impact
2.6 Obesity: Prevention and Treatment
2.6.1 Lifestyle changes
2.6.2 Pharmacotherapy
2.6.3 Other treatments
3. Introduction to the Global Anti-Obesity Drugs Market
3.1 Market Structure
3.2 Market Definition and Scope
3.3 Classification by Mechanism of Action
3.3.1 Incretin Mimetics/GLP-1 Agonists
3.3.2 Lipase Inhibitors
3.3.3 Serotonin-norepinephrine-dopamine Reuptake (SNDRI) Inhibitors
3.3.4 Serotonin Receptor Agonists
3.3.5 Sympathomimetics
3.3.6 Sympathomimetic-GABA Receptor Agonists
3.3.7 Others
3.4 Classification by Innovator or Generics Drugs
3.4.1 Innovator Drugs
3.4.2 Generics Drugs
3.5 Classification by Prescription or OTC drugs
3.5.1 Prescription drugs
3.5.2 OTC drugs
3.6 Classification by Duration of Therapy
3.6.1 Short-term drugs
3.6.2 Long-term drugs
4. Global Anti-Obesity Drugs Market 2017-2027
4.1 Global Anti-Obesity Drugs Market 2016
4.2 Global Anti-Obesity Drugs Market Forecast 2017-2027
4.3 Market Segmentation by Mechanism of Action
4.3.1 Forecast 2017-2027
4.3.1.1 Incretin mimetics/GLP-1 Agonists
4.3.1.2 Lipase Inhibitors
4.3.1.3 Serotonin-norepinephrine-dopamine Reuptake Inhibitors (SNDRI)
4.3.2 Serotonin Receptor Agonists
4.3.2.1 Sympathomimetic-GABA Receptor Agonists
4.3.2.2 Sympathomimetics
4.3.2.3 Others
4.3.3 Market Share Forecast 2017-2027
4.4 Market Segmentation by Innovator and Generics Drugs
4.4.1 Forecast 2017-2027
4.4.1.1 Innovator Drugs
4.4.1.2 Generics
4.4.2 Market Share Forecast 2017-2027
4.5 Market Segmentation by Prescription and OTC Drugs
4.5.1 Forecast 2017-2027
4.5.1.1 Prescription Drugs
4.5.1.2 OTC Drugs
4.5.2 Market Share Forecast 2017-2027
4.6 Market Segmentation by Duration of Therapy
4.6.1 Forecast 2017-2027
4.6.1.1 Short-term Anti-Obesity Drugs
4.6.1.2 Long-term Anti-Obesity Drugs
4.6.2 Market Share Forecast 2017-2027
4.7 Overall Global Anti-Obesity Drugs Market Drivers, Restraints and Trends
5. Leading Anti-Obesity Drugs
5.1 Snapshot of Anti-Obesity Drugs’ 2016 Sales, Historical Sales, & Forecast 2017-2027
5.2 Innovator Drugs
5.2.1 Saxenda
5.2.1.1 Drug Profile
5.2.1.2 Historical Sales
5.2.1.3 Forecast 2017-2027
5.2.1.4 Sales by Geography, 2016
5.2.2 Contrave / Mysimba
5.2.2.1 Drug Profile
5.2.2.2 Historical Sales
5.2.2.3 Forecast 2017-2027
5.2.2.4 Sales by Geography, 2016
5.2.3 Belvig
5.2.3.1 Drug Profile
5.2.3.2 Historical Sales
5.2.3.3 Forecast 2017-2027
5.2.3.4 Sales by Geography, 2016
5.2.4 Qysmia
5.2.4.1 Historical Sales
5.2.4.2 Forecast 2017-2027
5.2.5 Xenical and Alli
5.2.5.1 Historical Sales
5.2.5.2 Sales by Geography, 2016
5.2.5.3 Forecast 2017-2027
5.2.6 Cametor/Oblean
5.2.7 Lomaira
5.3 Generics
5.3.1 Orlistat
5.3.1.1 Historical Sales
5.3.2 Sibutramine
5.3.2.1 Historical Sales
5.3.3 Adipex
5.3.3.1 Historical Sales
5.3.4 Phentermine
5.3.4.1 Historical Sales
6. Leading National Markets Forecast 2017-2027
6.1 Geographical Breakdown of Global Anti-Obesity Drugs Market, 2016
6.1.1 Region-wise Breakdown of Global Anti-Obesity Drugs Market, 2016
6.1.2 Country-wise Breakdown of Global Anti-Obesity Drugs Market, 2016
6.2 Region-wise Forecast of Global Anti-Obesity Drugs Market, 2017-2027
6.3 Anti-obesity Drugs Market in the US, 2016
6.3.1 Market Forecast of the US, 2017-2027
6.4 Anti-obesity Drugs Market in the EU5 Region, 2016
6.4.1 Market Forecast of the EU5 Countries, 2017-2027
6.4.1.1 The UK
6.4.1.2 Spain
6.4.1.3 Italy
6.4.1.4 Germany
6.4.1.5 France
6.5 Anti-Obesity Drugs Market in the BRIC Region, 2016
6.5.1 Market Forecast of the BRIC Countries
6.5.1.1 Brazil
6.5.1.2 Russia
6.5.1.3 India
6.5.1.4 China
6.6 Anti-Obesity Drugs Market in Japan Region, 2016
7. Research and Development for Treating Obesity
7.1 Novel Mechanism of Action of Pipeline Drugs
7.2 Active Pipeline Molecules
7.3 Promising Potential Pipeline Molecules
7.3.1 Phase III Molecules
7.3.1.1 BTI-320
7.3.2 Phase II Molecules
7.3.2.1 Oxyntolong
7.3.2.2 Antisense FGFR4 oligo, Verva
7.3.2.3 S-237648
7.3.2.4 Setmelanotide
7.3.2.5 Bupropion + zonisamide SR
7.3.2.6 Semaglutide
7.3.2.7 LIK066
7.3.2.8 Tesofensine
7.3.2.9 LIPO-202
7.3.2.10 Canagliflozin and Phentermine
7.3.2.11 OBEP-100
7.3.2.11.1 Efpeglenatide
7.3.2.12 EMP16
7.3.2.13 MEDI-0382
8. Pricing and Reimbursement Overview
8.1 US
8.2 EU
8.3 Payers Perspective
9. Leading Companies in Global Anti-Obesity Drugs Market, 2016
9.1 Novo Nordisk
Source: Visiongain 2017
9.1.1 Obesity Care – To Establish its presence
9.2 Orexigen/Takeda
9.2.1 Collaboration Agreement with Takeda Pharmaceutical Company Limited
9.2.2 Collaboration Agreement with Valeant
9.3 Arena/Eisai
9.3.1 Collaboration Agreement with Eisai Co., Ltd.
9.3.2 Collaboration Agreement with Other Companies
9.4 F. Hoffmann-La Roche Ltd.
9.5 Vivus
9.6 Teva
9.7 GSK Consumer Healthcare
10. Executive Summary and Recommendations
Associated Visiongain Reports
Visiongain Report Sales Order Form
About Visiongain
Visiongain report evaluation form
List of Tables
Table 2.1: WHO BMI Cut Off Points
Table 2.2 Classification of Overweight and Obesity by BMI, Waist Circumference, and Associated Disease Risk
Table 2.3 Forecast of Obesity Prevalence in Major Markets (US, EU5, BRIC, and Japan), Both Sexes, aged >18 years, 2016-2027, million, CAGR (2016-2027) %
Table 3.1 Mechanism of Action of Innovator Drugs for the treatment of Obesity
Table 3.2 List of Innovator Drugs for the treatment of Obesity
Table 3.3 List of Prescription Drugs for the treatment of Obesity
Table 3.4 Long-term Prescription Drugs for the treatment of Obesity
Table 4.1 Global Anti-Obesity Drugs Market by Submarkets: Revenue ($m), and Market Share (%), 2016
Table 4.2 Global Anti-Obesity Drugs Market Forecast 2016-2027: Revenue ($m), AGR (%), CAGR (%)
Table 4.3 Global Anti-Obesity Drugs Market Segmentation by Mechanism of Action 2016-2027: Revenue ($m), AGR (%), CAGR (%)
Table 4.4 Global Anti-Obesity Drugs Market Segmentation by Mechanism of Action 2016-2027: AGR (%)
Table 4.5 Global Anti-Obesity Incretin mimetics/GLP-1 Agonist Drugs Market 2016-2027: Revenue ($m), AGR (%), CAGR (%)
Table 4.6 List of Active GLP-1 agonists in Clinical Pipeline
Table 4.7 Global Anti-Obesity Lipase Inhibitor Drugs Market 2016-2027: Revenue ($m), AGR (%), CAGR (%)
Table 4.8 List of Active SNDRI agonists in Clinical Pipeline
Table 4.9 Global Anti-Obesity Serotonin-norepinephrine-Dopamine Reuptake Inhibitor Drugs Market 2016-2027: Revenue ($m), AGR (%), CAGR (%)
Table 4.10 Global Anti-Obesity Serotonin Receptor Agonist Drugs Market 2016-2027: Revenue ($m), AGR (%), CAGR (%)
Table 4.11 Global Anti-Obesity Sympathomimetic-GABA Receptor Agonist Drugs Market 2016-2027: Revenue ($m), AGR (%), CAGR (%)
Table 4.12 Global Anti-Obesity Sympathomimetic Drugs Market 2016-2027: Revenue ($m), AGR (%), CAGR (%)
Table 4.13 Global Anti-Obesity Other Drugs Market 2016-2027: Revenue ($m), AGR (%), CAGR (%)
Table 4.14 Global Anti-Obesity Drugs Market Segmentation by Mechanism of Action 2016-2027: Market Share (%)
Source: Visiongain 2017
Table 4.15 Global Anti-Obesity Drugs Market Segmentation by Innovator Drugs and Generics 2016-2027: Revenue ($m), AGR (%), CAGR (%)
Table 4.16 Global Anti-Obesity Drugs Market Segmentation by Innovator Drugs and Generics 2016-2027: AGR (%)
Table 4.17 Global Anti-Obesity Innovator Drugs Market 2016-2027: Revenue ($m), AGR (%), CAGR (%)
Table 4.18 Global Anti-Obesity Generic Drugs Market 2016-2027: Revenue ($m), AGR (%), CAGR (%)
Table 4.19 Global Anti-Obesity Drugs Market Segmentation by Innovator Drugs and Generics 2016-2027: Market Share (%)
Source: Visiongain 2017
Table 4.20 Global Anti-Obesity Drugs Market Segmentation by Prescription and OTC Drugs 2016-2027: Revenue ($m), AGR (%), CAGR (%)
Table 4.21 Global Anti-Obesity Drugs Market Segmentation by Prescription and OTC Drugs 2016-2027: AGR (%)
Table 4.22 Global Anti-Obesity Prescription Drugs Market 2016-2027: Revenue ($m), AGR (%), CAGR (%)
Table 4.23 Global Anti-obesity OTC Drugs Market 2016-2027: Revenue ($m), AGR (%), CAGR (%)
Table 4.24 Global Anti-Obesity Drugs Market Segmentation by Prescription and OTC Drugs 2016-2027: Market Share (%)
Source: Visiongain 2017
Table 4.25 Global Anti-Obesity Drugs Market Segmentation by Duration of Therapy 2016-2027: Revenue ($m), AGR (%), CAGR (%)
Table 4.26 Global Anti-Obesity Drugs Market Segmentation by Duration of Therapy 2016-2027: AGR (%)
Table 4.27 Global Anti-Obesity Short-term Drugs Market 2016-2027: Revenue ($m), AGR (%), CAGR (%)
Table 4.28 Global Anti-Obesity Long-term Drugs Market 2016-2027: Revenue ($m), AGR (%), CAGR (%)
Table 4.29 Global Anti-Obesity Drugs Market Segmentation by Duration of Therapy 2016-2027: Market Share (%)
Source: Visiongain 2017
Table 5.1 Leading Anti-Obesity Drug Sales, Revenue($m), Market Share (%), 2016
Table 5.2 Saxenda Sales Forecast 2016-2027: Revenue ($m), AGR (%), CAGR (%)
Table 5.3 Contrave Sales Forecast 2016-2027: Revenue ($m), AGR (%), CAGR (%)
Table 5.4 Belvig Sales Forecast 2016-2027: Revenue ($million), AGR (%), CAGR (%)
Table 5.5 Qysmia Sales Forecast 2016-2027: Revenue ($m), AGR (%), CAGR (%)
Table 5.6 Alli Sales Forecast 2016-2027: Revenue ($m), AGR (%), CAGR (%)
Table 6.1 Global Anti-Obesity Drugs Market by Region: Revenue ($m), and Market Share (%), 2016
Table 6.2 Global Anti-Obesity Drugs Market by Country: Revenue ($m), and Market Share (%), 2016
Table 6.3 Global Anti-Obesity Drugs Market Forecast by Region: Revenue ($m), AGR (%), CAGR (%),2016-2027
Table 6.4 Global Anti-Obesity Drugs Market by Region: AGR 2016-2027 (%)
Source: Visiongain 2017
Table 6.5 Global Anti-Obesity Drugs Market by Region: Market Share Forecast 2017-2027 (%)
Source: Visiongain 2017
Table 6.6 Anti-Obesity Drugs Market Forecast in the US 2016-2027: Revenue ($m), AGR (%), CAGR (%)
Table 6.7 Anti-obesity Drugs Market Forecast in EU5 Region: Revenue ($m), AGR (%), CAGR (%), 2016-2027
Table 6.8 Anti-obesity Drugs Market by EU Region: Market Share Forecast 2017-2027 (%)
Source: Visiongain 2017
Table 6.9 Anti-Obesity Drugs Market Forecast by EU5 Region: AGR 2016-2027 (%)
Source: Visiongain 2017
Table 6.10 Anti-Obesity Drugs Market Forecast in the UK: Revenue ($m), AGR (%), CAGR (%), 2016-2027
Table 6.11 Anti-obesity Drugs Market Forecast in Spain: Revenue ($m), AGR (%), CAGR (%), 2016-2027
Table 6.12 Anti-obesity Drugs Market Forecast in Italy: Revenue ($m), AGR (%), CAGR (%), 2016-2027
Table 6.13 Anti-Obesity Drugs Market Forecast in Germany: Revenue ($m), AGR (%), CAGR (%), 2016-2027
Table 6.14 Anti-Obesity Drugs Market Forecast in France: Revenue ($m), AGR (%), CAGR (%), 2016-2027
Table 6.15 Anti-Obesity Drugs Market Forecast in BRIC Region: Revenue ($m), AGR (%), CAGR (%), 2016-2027
Table 6.16 Anti-Obesity Drugs Market Forecast in Brazil Region: Revenue ($m), AGR (%), CAGR (%), 2016-2027
Table 6.17 Anti-Obesity Drugs Market Forecast in Russia Region: Revenue ($m), AGR (%), CAGR (%), 2016-2027
Table 6.18 Anti-Obesity Drugs Market Forecast in India Region: Revenue ($m), AGR (%), CAGR (%), 2016-2027
Table 6.19 Anti-Obesity Drugs Market Forecast in China: Revenue ($m), AGR (%), CAGR (%), 2016-2027
Table 6.20 Anti-Obesity Drugs Market Forecast in Japan: Revenue ($m), AGR (%), CAGR (%), 2016-2027
Table 7.1 Active Pipeline Molecules under Development for Treating Obesity
Table 9.1 Innovator Drugs’ Originator-Licensee Information
Table 9.2 Novo Nordisk A/S: Overview 2016
Table 9.3 Novo Nordisk: List of Active Clinical Pipeline Molecules
Table 9.4 Orexigen: Overview 2016
Table 9.5 Arena: Overview 2016
Table 9.6 Roche: Overview 2016
Table 9.7 Vivus: Overview 2016
List of Figures
Figure 2.1 Prevalence of Overweight and Obese Population by WHO Region, Ages 18+, 2014
Figure 2.2 Prevalence of Overweight, Ages 18+, 2010-2014, Age Standardized Estimate: Both Sexes 2014
Figure 2.3 Prevalence of Obesity, Ages 18+, 2010-2014, Age Standardized Estimate: Both Sexes 2014
Figure 2.4 Prevalence of Obesity in OECD 32 Countries – population aged 15 years and over, 2013 or nearest year
Figure 2.5 Prevalence of Obesity in G7 and BRIC Countries – population aged 15 years and over, 2012 or nearest year, men, women, both sexes
Figure 2.6 Age-Standardized Obesity Prevalence Rate in Major Markets – Population aged 15 years and over, 1973-2012
Figure 2.7 Deaths due to Obesity in G7 and BRIC Nation: Absolute Number (000’s), 2015
Figure 2.8 DALY’s due to Obesity in G7 and BRIC Nation: Absolute Number (million), 2015
Figure 2.9 YLD’s due to Obesity in G7 and BRIC Nation: Absolute Number (million), 2015
Figure 2.10 YLL’s due to Obesity in G7 and BRIC Nation: Absolute Number (000’s), 2015
Figure 3.1 Global Anti-obesity Drugs Market Segmentation Overview
Figure 3.2 Anti-Obesity Drugs Classification by Mechanism of Action, 2016
Figure 4.1 Global Anti-Obesity Drugs Market Segmentation by Mechanism of Action, Market Share 2016 (%)
Figure 4.2 Global Anti-Obesity Drugs Market Segmentation by Innovator Drugs and Generics, Market Share 2016 (%)
Figure 4.3 Global Anti-Obesity Drugs Market Segmentation by Prescription and OTC Drugs, Market Share 2016 (%)
Figure 4.4 Global Anti-Obesity Drugs Market Segmentation by Duration of Therapy, Market Share 2016 (%)
Figure 4.5 Global Anti-Obesity Drugs Market Forecast 2016-2027: Revenue ($m), AGR (%)
Figure 4.6 Global Anti-Obesity Drugs Market Size of Markets by Mechanism of Action 2016, Revenue ($m)
Figure 4.7 Global Anti-Obesity Drugs Market Segmentation by Mechanism of Action, Market Share 2016 (%)
Figure 4.8 Global Anti-obesity Drugs Market Segmentation by Mechanism of Action 2016-2027: Revenue ($m), Global AGR (%)
Figure 4.9 Global Anti-Obesity Drugs Market Segmentation by Mechanism of Action 2016 and 2027: Revenue ($m), CAGR 2016-2027(%)
Figure 4.10 Global Anti-Obesity Drugs Market Segmentation by Mechanism of Action 2016-2027: AGR (%)
Figure 4.11 Global Anti-Obesity Incretin mimetics/GLP-1 Agonist Drugs Market 2016-2027: Revenue ($m), AGR (%)
Figure 4.12 Global Anti-Obesity Lipase Inhibitor Drugs Market 2016-2027: Revenue ($m), AGR (%)
Figure 4.13 Global Anti-Obesity Serotonin-norepinephrine-Dopamine Reuptake Inhibitor Drugs Market 2016-2027: Revenue ($m), AGR (%)
Figure 4.14 Global Anti-Obesity Serotonin Receptor Agonist Drugs Market 2016-2027: Revenue ($m), AGR (%)
Figure 4.15 Global Anti-Obesity Sympathomimetic-GABA Receptor Agonist Drugs Market 2016-2027: Revenue ($m), AGR (%)
Figure 4.16 Global Anti-Obesity Sympathomimetic Drugs Market 2016-2027: Revenue ($m), AGR (%)
Figure 4.17 Global Anti-Obesity Other Drugs Market 2016-2027: Revenue ($m), AGR (%)
Figure 4.18 Global Anti-Obesity Drugs Market Segmentation by Mechanism of Action 2016-2027: Market Share (%)
Figure 4.19 Global Anti-Obesity Drugs Market Segmentation by Mechanism of Action: Market Share Forecast 2017 (%)
Figure 4.20 Global Anti-Obesity Drugs Market Segmentation by Mechanism of Action: Market Share 2027 (%)
Figure 4.21 Global Anti-Obesity Drugs Market Segmentation by Innovator Drugs and Generics, Revenue 2016 ($m)
Figure 4.22 Global Anti-Obesity Drugs Market Segmentation by Innovator Drugs and Generics, Market Share 2016 (%)
Figure 4.23 Global Anti-Obesity Drugs Market Segmentation by Innovator Drugs and Generics 2016-2027: Revenue ($m), Global AGR (%)
Figure 4.24 Global Anti-Obesity Drugs Market Segmentation by Innovator Drugs and Generics: Revenue 2016 and 2027 ($m), CAGR 2016-2027 (%)
Figure 4.25 Global Anti-Obesity Drugs Market Segmentation by Innovator Drugs and Generics 2016-2027: AGR (%)
Figure 4.26 Global Anti-Obesity Innovator Drugs Market 2016-2027: Revenue ($m), AGR (%)
Figure 4.27 Global Anti-Obesity Generic Drugs Market 2016-2027: Revenue ($m), AGR (%)
Figure 4.28 Global Anti-Obesity Drugs Market Segmentation by Innovator Drugs and Generics 2016-2027: Market Share (%)
Figure 4.29 Global Anti-Obesity Drugs Market Segmentation by Innovator Drugs and Generics, Market Share Forecast 2017 (%)
Figure 4.30 Global Anti-Obesity Drugs Market Segmentation by Innovator Drugs and Generics: Market Share Forecast 2027 (%)
Figure 4.31 Global Anti-Obesity Drugs Market Segmentation by Prescription and OTC Drugs, Revenue 2016 ($m)
Figure 4.32 Global Anti-Obesity Drugs Market Segmentation by Prescription and OTC Drugs, Market Share 2016 (%)
Figure 4.33 Global Anti-Obesity Drugs Market Segmentation by Prescription and OTC Drugs 2016-2027: Revenue ($m), Global AGR (%)
Figure 4.34 Global Anti-obesity Drugs Market Segmentation by Prescription and OTC Drugs: Revenue 2016 and 2027 ($m), CAGR 2016-2027 (%)
Figure 4.35 Global Anti-Obesity Drugs Market Segmentation by Prescription and OTC Drugs 2016-2027: AGR (%)
Figure 4.36 Global Anti-Obesity Prescription Drugs Market 2016-2027: Revenue ($m), AGR (%)
Figure 4.37 Global Anti-obesity OTC Drugs Market 2016-2027: Revenue ($m), AGR (%)
Figure 4.38 Global Anti-Obesity Drugs Market Segmentation by Prescription and OTC Drugs 2016-2027: Market Share (%)
Figure 4.39 Global Anti-Obesity Drugs Market Segmentation by Prescription and OTC Drugs, Market Share Forecast 2017 (%)
Figure 4.40 Global Anti-Obesity Drugs Market Segmentation by Prescription and OTC Drugs: Market Share Forecast 2027 (%)
Figure 4.41 Global Anti-Obesity Drugs Market Segmentation by Duration of Therapy, Revenue 2016 ($m)
Figure 4.42 Global Anti-Obesity Drugs Market Segmentation by Duration of Therapy, Market Share 2016 (%)
Figure 4.43 Global Anti-Obesity Drugs Market Segmentation by Duration of Therapy 2016-2027: Revenue ($m)
Figure 4.44 Global Anti-Obesity Drugs Market Segmentation by Duration of Therapy: Revenue 2016 and 2027 ($m), CAGR 2016-2027 (%)
Figure 4.45 Global Anti-Obesity Drugs Market Segmentation by Duration of Therapy 2016-2027: AGR (%)
Figure 4.46 Global Anti-Obesity Short-term Drugs Market 2016-2027: Revenue ($m), AGR (%)
Figure 4.47 Global Anti-Obesity Long-term Drugs Market 2016-2027: Revenue ($m), AGR (%)
Figure 4.48 Global Anti-Obesity Drugs Market Segmentation by Duration of Therapy 2016-2027: Market Share (%)
Figure 4.49 Global Anti-Obesity Drugs Market Segmentation by Duration of Therapy, Market Share Forecast 2017 (%)
Figure 4.50 Global Anti-Obesity Drugs Market Segmentation by Duration of Therapy: Market Share Forecast 2027 (%)
Figure 4.51 Trends in Global Anti-Obesity Drugs Market
Figure 4.52 SWOT Analysis of the Global Anti-Obesity Drugs Market
Figure 5.1 Leading Anti-Obesity Drug Sales, Revenue ($m), 2016
Figure 5.2 Leading Anti-Obesity Drug Sales, Market Share (%), 2016
Figure 5.3 Anti-Obesity Drugs Sales Forecast, Market Share (%), 2027
Figure 5.4 Leading Anti-Obesity Drugs, Historical Sales, Revenue ($m), 2011-2016
Figure 5.5 Anti-Obesity Drugs, Historical Sales Trend, Revenue ($m), 2011-2016
Figure 5.6 Global Anti-Obesity Innovator Drugs Market, Market Share by Individual Drug (%), 2016
Figure 5.7 Global Anti-Obesity Innovator Drugs Market Forecast, Market Share by Individual Drug (%), 2027
Figure 5.8 Saxenda Global Sales: Revenue ($million), 2015-2016
Figure 5.9 Saxenda Sales Forecast 2016-2027: Revenue ($m), AGR (%)
Figure 5.10 Saxenda Sales by Geography: Market Share (%), 2016
Figure 5.11 Contrave Global Sales: Revenue ($million), 2014-2016
Figure 5.12 Contrave Sales Forecast 2016-2027: Revenue ($million), AGR (%)
Figure 5.13 Contrave Sales by Geography: Market Share (%), 2016
Figure 5.14 Belviq Global Sales: Revenue ($million), 2013-2016
Figure 5.15 Belvig Sales Forecast 2016-2027: Revenue ($million), AGR (%)
Figure 5.16 Belviq Sales by Geography: Market Share (%), 2016
Figure 5.17 Qysmia Global Sales: Revenue ($million), 2013-2016
Figure 5.18 Qysmia Sales Forecast 2016-2027: Revenue ($million), AGR (%)
Figure 5.19 Qysmia Sales by Geography: Market Share (%), 2016
Figure 5.20 Xenical Global Sales: Revenue ($million), 2011-2016
Figure 5.21 Alli Global Sales: Revenue ($million), 2011-2016
Figure 5.22 Xenical Sales by Geography: Market Share (%), 2016
Figure 5.23 Alli Sales by Geography: Market Share (%), 2016
Figure 5.24 Alli Sales Forecast 2016-2027: Revenue ($m), AGR (%)
Figure 5.25 Global Anti-obesity Generics Market, Market Share by Individual Compound (%), 2016
Figure 5.26 Orlistat Global Sales: Revenue ($m), 2011-2016
Figure 5.27 Sibutramine Global Sales: Revenue ($million), 2011-2016
Figure 5.28 Adipex Global Sales: Revenue ($million), 2011-2016
Figure 5.29 Phentermine Global Sales: Revenue ($m), 2011-2016
Figure 6.1 Global Anti-Obesity Drugs Market Segmentation by Region/Country
Figure 6.2 Global Anti-Obesity Drugs Market by Region: Revenue ($m)
Figure 6.3 Global Anti-Obesity Drugs Market by Region: Market Share 2016 (%)
Figure 6.4 Global Anti-Obesity Drugs Market by Country: Revenue ($m), 2016
Figure 6.5 Global Anti-Obesity Drugs Market by Country: Market Share (%), 2016
Figure 6.6 Global Anti-Obesity Drugs Market Forecast by Region: Revenue ($m), Global AGR (%), 2016-2027
Figure 6.7 Global Anti-Obesity Drugs Market Forecast by Region 2016, 2022, 2027: Revenue ($m), CAGR 2016-2027 (%)
Figure 6.8 Global Anti-Obesity Drugs Market by Region: AGR 2016-2027 (%)
Figure 6.9 Global Anti-Obesity Drugs Market by Region: Market Share Forecast 2017-2027 (%)
Figure 6.10 Global Anti-Obesity Drugs Market by Region: Market Share Forecast 2017 (%)
Figure 6.11 Global Anti-Obesity Drugs Market by Region: Market Share Forecast 2022 (%)
Figure 6.12 Global Anti-Obesity Drugs Market by Region: Market Share Forecast 2027 (%)
Figure 6.13 Anti-obesity Drugs Market in the US: 2016 Revenue ($m), Market Share %
Figure 6.14 Anti-obesity Drugs Market Forecast in the US 2016-2027: Revenue ($m), AGR (%)
Figure 6.15 Anti-obesity Drugs Market in the EU5 2016: Global Market Share (%)
Figure 6.16 Anti-Obesity Drugs Market in the EU5 Countries 2016: Market Share (%)
Figure 6.17 Anti-Obesity Drugs Market Forecast in the EU5 Countries 2016-2027: Revenue ($m), EU5 AGR (%)
Figure 6.18 Anti-Obesity Drugs Market Forecast in the EU5 Countries 2016 and 2027: Revenue ($m), CAGR 2016-2027 (%)
Figure 6.19 Anti-Obesity Drugs Market by EU5 Region: Market Share Forecast 2017-2027 (%)
Figure 6.20 Anti-Obesity Drugs Market Forecast by EU5 Region: Global Market Share 2027(%)
Figure 6.21 Anti-Obesity Drugs Market Forecast by EU5 Region: Market Share 2017(%)
Figure 6.22 Anti-Obesity Drugs Market Forecast by EU5 Region: Market Share 2027 (%)
Figure 6.23 Global Anti-Obesity Drugs Market Forecast by EU5 Region: AGR 2016-2027 (%)
Figure 6.24 Anti-Obesity Drugs Market Forecast in the UK: Revenue ($m), AGR (%),2016-2027
Figure 6.25 Anti-obesity Drugs Market Forecast in Spain: Revenue ($m), AGR (%), 2016-2027
Figure 6.26 Anti-Obesity Drugs Market Forecast in Italy: Revenue ($m), AGR (%), 2016-2027
Figure 6.27 Anti-Obesity Drugs Market Forecast in Germany: Revenue ($m), AGR (%), 2016-2027
Figure 6.28 Anti-Obesity Drugs Market Forecast in France: Revenue ($m), AGR (%), 2016-2027
Figure 6.29 Anti-Obesity Drugs Market in the BRIC Region: Global Market Share 2016 (%)
Figure 6.30 Anti-Obesity Drugs Market in the BRIC Countries 2016: Market Share (%)
Figure 6.31 Anti-Obesity Drugs Market Forecast in the BRIC Countries 2016-2027: Revenue ($m), BRIC AGR (%)
Figure 6.32 Anti-Obesity Drugs Market Forecast in the BRIC Countries 2016 and 2027: Revenue ($m), CAGR 2016-2027 (%)
Figure 6.33 Anti-Obesity Drugs Market Forecast by BRIC Region: Global Market Share 2027(%)
Figure 6.34 Anti-Obesity Drugs Market Forecast by BRIC Region: Market Share 2017(%)
Figure 6.35 Anti-Obesity Drugs Market Forecast by BRIC Region: Market Share 2027 (%)
Figure 6.36 Anti-Obesity Drugs Market Forecast in the Brazil: Revenue ($m), AGR (%), 2016-2027
Figure 6.37 Anti-Obesity Drugs Market Forecast in the Russia: Revenue ($m), AGR (%),2016-2027
Figure 6.38 Anti-Obesity Drugs Market Forecast in the India: Revenue ($m), AGR (%),2016-2027
Figure 6.39 Anti-Obesity Drugs Market Forecast in China: Revenue ($m), AGR (%),2016-2027
Figure 6.40 Anti-Obesity Drugs Market Forecast in Japan: Revenue ($m), AGR (%),2016-2027
Figure 7.1 Anti-obesity Clinical Pipeline Segmentation by Phase, 2016
Figure 7.2 Anti-obesity Pipeline Segmentation by Mechanism of Action, 2016
Figure 9.1 Global Anti-Obesity Drugs Market by Company: Revenue ($m)
Figure 9.2 Global Anti-Obesity Drugs Market by Company 2016: Market Share (%)
Figure 9.3 Novo Nordisk’s 20-year R&D journey in Obesity - Milestones of Saxenda
Figure 10.1 Forecast of Obesity Prevalence in US, EU5, BRIC and Japan, ages 18+, Both sexes, 2016-2027
Figure 10.2 Global Anti-Obesity Drugs Market Forecast 2016-2027: Revenue ($m), AGR (%)
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
